Europe’s Innovative Medicines Initiative (IMI) and the US Critical Path Institute (C-Path) have signed a Memorandum of Understanding to further their shared mission of reshaping the drug development process to bring safer and more effective products to market more quickly. Both organizations bring together scientists from industry and academia, as well as representatives from patient organizations, small companies and regulatory agencies, in precompetitive public-private partnerships. With this agreement, IMI and C-Path will look for opportunities to leverage one another’s work, further accelerated progress and prevent duplication.
Read more: